Success! You're on the list.

Success! You're on the list.

Foresite Capital closes $900M healthcare and life sciences venture fund

Foresite Capital team
Picture credits:

San Francisco-based Foresite Capital, a multi-stage healthcare and life sciences investment firm, has closed its sixth fund with $900 million in capital commitments.  

Limited partners of Fund VI include a broad range of investors, including university endowments, charitable foundations, medical institutions, pension funds, insurance companies, private banks, and family offices worldwide. 

Investment plans

With this new fund, Foresite Capital continues to invest in groundbreaking technologies, ranging from novel therapeutics to companies at the intersection of technology and biotechnology. 

Fund VI specifically targets three key areas of growth:

  • Precision Therapeutics: Targeting treatments to individual patient needs for improved efficacy and outcomes.
  • Life Science Infrastructure: Investing in companies that provide critical support and services within the life sciences industry.
  • Healthcare Delivery: Funding solutions for more efficient and accessible healthcare delivery models.

Healthcare and life sciences investment firm 

Founded in 2011, Foresite Capital is based in the San Francisco Bay Area, Los Angeles, and New York City. With over $3.5 billion under management, it aims to address areas of unmet medical need by funding promising healthcare and life sciences businesses at all stages of their life cycles.

To date, the investment firm has adhered to a data and science-driven investment strategy, resulting in over 47 IPOs, 28 mergers and acquisitions, and the approval of 58 drugs by the FDA. 

Foresite’s team offers comprehensive support to its portfolio companies, leveraging expertise in company formation, therapeutics product development, and data science/machine learning to provide strategic guidance and technical assistance.

Foresite Capital’s Fund VI portfolio already includes several promising companies like Alumis, CG Oncology, Latigo, RayThera, Evonetix, and Xaira Therapeutics.

“Fund VI is deploying capital into what I believe is one of the best biotech investment environments of my career,” said JimTananbaum, founder and CEO of Foresite Capital. “Advances in biology, genomics, and artificial intelligence continue to converge. Biotech innovation is predicting, preventing, and treating disease more effectively than ever before. We believe these advances will lead to increasingly efficient investing at all stages.”

“We’re grateful for the support we’ve received from both long-standing partners and new investors alike,” said Hadi Tabbaa, Managing Director and Head of Investor Relations and Business Development. “Their partnership with Foresite Capital enables our support of entrepreneurs who are addressing some of the most vexing aspects of our healthcare system and improving the lives of patients.” 

What do we think about Foresite Capital?

Their new $900 million Fund VI targets precision therapeutics, life science infrastructure, and healthcare delivery, promising innovative advancements in biotechnology and healthcare solutions. It plans to address the unmet medical need by funding promising healthcare and life sciences businesses. 

Related Posts

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you